|
Market Closed -
Nasdaq
00:00:00 28/08/2026 +04
|
5-day change | 1st Jan Change | ||
| 543.69 USD | +0.89% |
|
+4.74% | -6.64% |
Company Valuation: Madrigal Pharmaceuticals, Inc.
Data adjusted to current consolidation scope
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|---|---|
| Market Cap 1 | 1,449 | 5,179 | 4,568 | 6,730 | 13,226 | 12,561 | - | - |
| Change | - | 257.45% | -11.79% | 47.33% | 96.52% | -5.02% | - | - |
| Enterprise Value (EV) 1 | 1,179 | 4,869 | 4,051 | 5,922 | 12,584 | 12,037 | 11,618 | 10,511 |
| Change | - | 313.04% | -16.81% | 46.21% | 112.48% | -4.35% | -3.48% | -9.53% |
| P/E | -5.79x | -16.8x | -11.6x | -14.1x | -45.3x | -86.1x | 86.4x | 23.9x |
| PBR | 7.15x | 26.6x | 11.3x | 9x | 22.1x | 28x | 15.3x | 7.56x |
| PEG | - | -0.9x | -0.7x | -1.48x | 1.1x | 1.7x | -0x | 0x |
| Capitalization / Revenue | - | - | - | 37.4x | 13.8x | 8.23x | 5.86x | 4.3x |
| EV / Revenue | - | - | - | 32.9x | 13.1x | 7.89x | 5.42x | 3.6x |
| EV / EBITDA | -4.87x | -16.6x | -10.7x | -11.9x | -42.1x | -65.3x | 42.2x | 10.4x |
| EV / EBIT | -4.86x | -16.6x | -10.6x | -11.9x | -41.9x | -63.9x | 60.9x | 14.5x |
| EV / FCF | -4.87x | -16.6x | -12.4x | -13x | -66.2x | -60x | 42.7x | 13.1x |
| FCF Yield | -20.6% | -6.01% | -8.04% | -7.72% | -1.51% | -1.67% | 2.34% | 7.62% |
| Dividend per Share 2 | - | - | - | - | - | - | - | - |
| Rate of return | - | - | - | - | - | - | - | - |
| EPS 2 | -14.63 | -17.23 | -19.99 | -21.9 | -12.85 | -6.314 | 6.295 | 22.7 |
| Distribution rate | - | - | - | - | - | - | - | - |
| Net sales 1 | - | - | - | 180.1 | 958.4 | 1,526 | 2,145 | 2,922 |
| EBITDA 1 | -242.1 | -293.1 | -380 | -496.8 | -298.6 | -184.3 | 275.3 | 1,014 |
| EBIT 1 | -242.5 | -293.6 | -380.5 | -497.9 | -300.1 | -188.3 | 190.7 | 726.9 |
| Net income 1 | -241.8 | -295.4 | -373.6 | -465.9 | -288.3 | -183.9 | 200 | 707.8 |
| Net Debt 1 | -269.9 | -309.5 | -517.5 | -807.7 | -642 | -524.5 | -943.2 | -2,051 |
| Reference price 2 | 84.74 | 290.25 | 231.38 | 308.57 | 582.34 | 543.69 | 543.69 | 543.69 |
| Nbr of stocks (in thousands) | 17,097 | 17,842 | 19,743 | 21,810 | 22,711 | 23,104 | - | - |
| Announcement Date | 24/02/22 | 23/02/23 | 28/02/24 | 26/02/25 | 19/02/26 | - | - | - |
1USD in Million2USD
Estimates
P/E, Detailed evolution
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -85.34x | 7.81x | -64.71x | -.--% | 12.45B | |
| 20.97x | 7.35x | 14.98x | 1.41% | 70.42B | |
| 37.32x | 9.68x | 29.71x | 0.04% | 65.4B | |
| -17.15x | 7.14x | -8.98x | -.--% | 28.28B | |
| -78.62x | 14.69x | -70.84x | -.--% | 27.16B | |
| 30.86x | 6.62x | 17.71x | -.--% | 26.57B | |
| 59.78x | 22.25x | 45.14x | 0.25% | 20.61B | |
| 27.31x | 5.12x | 17.18x | -.--% | 20.09B | |
| 1692.68x | 39.78x | 868.6x | -.--% | 15.87B | |
| 17.35x | 5.16x | 12.03x | -.--% | 13.9B | |
| Average | 170.52x | 12.56x | 86.08x | 0.17% | 30.08B | |
| Weighted average by Cap. | 99.55x | 10.94x | 52.25x | 0.36% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
Year-on-year evolution of the Yield
- Stock Market
- Stocks
- MDGL Stock
- Valuation Madrigal Pharmaceuticals, Inc.
Select your edition
All financial news and data tailored to specific country editions
